These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1844 related articles for article (PubMed ID: 15940470)

  • 21. Chemicals of emerging concern in the Great Lakes Basin: an analysis of environmental exposures.
    Klecka G; Persoon C; Currie R
    Rev Environ Contam Toxicol; 2010; 207():1-93. PubMed ID: 20652664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toxicity assessment strategies, data requirements, and risk assessment approaches to derive health based guidance values for non-relevant metabolites of plant protection products.
    Dekant W; Melching-Kollmuss S; Kalberlah F
    Regul Toxicol Pharmacol; 2010 Mar; 56(2):135-42. PubMed ID: 19883711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety assessment of personal care products/cosmetics and their ingredients.
    Nohynek GJ; Antignac E; Re T; Toutain H
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):239-59. PubMed ID: 20005888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methods for deriving pesticide aquatic life criteria.
    TenBrook PL; Tjeerdema RS; Hann P; Karkoski J
    Rev Environ Contam Toxicol; 2009; 199():19-109. PubMed ID: 19110939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
    Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Final report of the safety assessment of Alcohol Denat., including SD Alcohol 3-A, SD Alcohol 30, SD Alcohol 39, SD Alcohol 39-B, SD Alcohol 39-C, SD Alcohol 40, SD Alcohol 40-B, and SD Alcohol 40-C, and the denaturants, Quassin, Brucine Sulfate/Brucine, and Denatonium Benzoate.
    Cosmetic Ingredient Review Expert Panel
    Int J Toxicol; 2008; 27 Suppl 1():1-43. PubMed ID: 18569160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of dogs as second species in regulatory testing of pesticides. I. Interspecies comparison.
    Gerbracht U; Spielmann H
    Arch Toxicol; 1998 May; 72(6):319-29. PubMed ID: 9657278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of crop and non-crop plants as sensitive indicator species for regulatory testing.
    McKelvey RA; Wright JP; Honegger JL
    Pest Manag Sci; 2002 Dec; 58(12):1161-74. PubMed ID: 12476989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Background to the ADI/TDI/PTWI.
    Herrman JL; Younes M
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S109-13. PubMed ID: 10597623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling.
    Valerio LG; Arvidson KB; Chanderbhan RF; Contrera JF
    Toxicol Appl Pharmacol; 2007 Jul; 222(1):1-16. PubMed ID: 17482223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimising the design of preliminary toxicity studies for pharmaceutical safety testing in the dog.
    Smith D; Combes R; Depelchin O; Jacobsen SD; Hack R; Luft J; Lammens L; von Landenberg F; Phillips B; Pfister R; Rabemampianina Y; Sparrow S; Stark C; Stephan-Gueldner M
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):95-101. PubMed ID: 15698532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strengths and limitations of using repeat-dose toxicity studies to predict effects on fertility.
    Dent MP
    Regul Toxicol Pharmacol; 2007 Aug; 48(3):241-58. PubMed ID: 17512650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pesticide registration in the United States: overview and new directions.
    Culleen LE
    Qual Assur; 1994 Sep; 3(3):291-9. PubMed ID: 7804650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection.
    Rhomberg LR; Baetcke K; Blancato J; Bus J; Cohen S; Conolly R; Dixit R; Doe J; Ekelman K; Fenner-Crisp P; Harvey P; Hattis D; Jacobs A; Jacobson-Kram D; Lewandowski T; Liteplo R; Pelkonen O; Rice J; Somers D; Turturro A; West W; Olin S
    Crit Rev Toxicol; 2007; 37(9):729-837. PubMed ID: 17957539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
    Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
    Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amended final report on the safety assessment of polyacrylamide and acrylamide residues in cosmetics.
    Int J Toxicol; 2005; 24 Suppl 2():21-50. PubMed ID: 16154914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 93.